Reviewing C4 Therapeutics (NASDAQ:CCCC) and Arcturus Therapeutics (NASDAQ:ARCT)

C4 Therapeutics (NASDAQ:CCCC) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Earnings & Valuation

This table compares C4 Therapeutics and Arcturus Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.58 million	5.94	-$105.32 million	($1.67)	-1.31
Arcturus Therapeutics	$152.31 million	1.42	-$80.94 million	($2.46)	-3.09

Arcturus Therapeutics has higher revenue and earnings than C4 Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

C4 Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for C4 Therapeutics and Arcturus Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1	2	5	0	2.50
Arcturus Therapeutics	1	4	8	0	2.54

C4 Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 232.57%. Arcturus Therapeutics has a consensus target price of $34.00, suggesting a potential upside of 347.96%. Given Arcturus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than C4 Therapeutics.

Profitability

This table compares C4 Therapeutics and Arcturus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-395.51%	-64.40%	-38.69%
Arcturus Therapeutics	-68.35%	-28.68%	-21.05%

Institutional & Insider Ownership

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 8.7% of C4 Therapeutics shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Arcturus Therapeutics beats C4 Therapeutics on 10 of the 14 factors compared between the two stocks.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.